CRISPR Therapeutics AG (CRSP) vs TransMedics Group, Inc. (TMDX)
A side-by-side comparison of CRISPR Therapeutics AG and TransMedics Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
CRSP
CRISPR Therapeutics AG
$55.43HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
TMDX
TransMedics Group, Inc.
$79.80HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
Total return — CRSP vs TMDX
growth of $100 · dividends reinvested · last 7yCRSP +37.6% (+4.7%/yr)TMDX +251.7% (+19.7%/yr)TMDX compounded faster over this window
CRSP TMDX
CRSP vs TMDX: by the numbers
- •CRSP is the larger company ($5.35B vs $2.76B market cap).
- •TMDX is profitable (22.69% net margin) while CRSP runs a net loss (-3368.72%).
- •TMDX grew revenue faster over the past five years (86.12% vs 37.32% CAGR).
Metrics side by side
Valuation
| Metric | CRSP | TMDX |
|---|---|---|
| P/E ratio | N/A | 20.67 |
| Forward P/E | N/A | 54.40 |
| P/S ratio | 399.21 | 4.13 |
| P/B ratio | 3.06 | 5.32 |
| EV / EBITDA | N/A | 26.71 |
| FCF yield | N/A | 2.87% |
Profitability
| Metric | CRSP | TMDX |
|---|---|---|
| Gross margin | -6537.01% | 58.69% |
| Operating margin | -16191.40% | 12.21% |
| Net margin | -3368.72% | 22.69% |
| ROE | -25.83% | 29.28% |
| ROIC | -21.12% | 5.87% |
Growth (annualized)
| Metric | CRSP | TMDX |
|---|---|---|
| Revenue CAGR (5Y) | 37.32% | 86.12% |
| Total return CAGR (5Y) | -13.01% | 19.20% |
Frequently asked
- Which has grown faster, CRSP or TMDX?
- Over the past five years, TMDX grew revenue faster — CRSP at a 37.32% CAGR versus TMDX at 86.12%.
- Is CRSP or TMDX more profitable?
- TMDX runs the higher net margin — CRSP at -3368.72% versus TMDX at 22.69%.
- How have CRSP and TMDX total returns compared?
- Over the past 5 years, CRSP delivered -13.01% and TMDX delivered 19.20% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
TransMedics P/E ratioCRISPR Therapeutics AG ROETransMedics ROECRISPR Therapeutics AG operating marginTransMedics operating marginCRISPR Therapeutics AG revenue growthTransMedics revenue growthCRISPR Therapeutics AG free cash flowTransMedics free cash flow
CRISPR Therapeutics AG & TransMedics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.